Overview
Veracyte
Veracyte is a global genomic diagnostics company that aims to improve patient care through better diagnosis and treatment decisions for patients with cancer and other diseases. Aside from genomic tests, the company also offers its exclusive nCounter Analysis System, which Veracyte believes is the best-in-class diagnostics platform that enables the company to deliver tests to patients globally and hospitals locally. The company currently offers tests
...
Read More in thyroid cancer (Afirma); prostate cancer (Decipher Prostate); breast cancer (Prosigna); interstitial lung diseases (Envisia); and bladder cancer (Decipher Bladder). Its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. The US accounts for about 95% of the company's total revenue.
Read Less
Read More in thyroid cancer (Afirma); prostate cancer (Decipher Prostate); breast cancer (Prosigna); interstitial lung diseases (Envisia); and bladder cancer (Decipher Bladder). Its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. The US accounts for about 95% of the company's total revenue.
Read Less
Marc Stapley
See more contacts
Medical and Diagnostic Laboratories
,
Scientific Research and Development Services
,
Pharmaceutical and Medicine Manufacturing
,
Medical laboratories
,
Medical research
See All Industries Cytology and histology diagnostic agents
See Fewer Industries
See All Industries Cytology and histology diagnostic agents
See Fewer Industries
Child Care Services
,
Community Food and Housing, and Emergency and Other Relief Services
,
Continuing Care Retirement Communities and Assisted Living Facilities for the Elderly
,
General Medical and Surgical Hospitals
,
Home Health Care Services
,
Individual and Family Services
,
Nursing Care Facilities (Skilled Nursing Facilities)
,
Offices of Dentists
View more , Offices of Other Health Practitioners , Offices of Physicians , Other Ambulatory Health Care Services , Other Residential Care Facilities , Outpatient Care Centers , Psychiatric and Substance Abuse Hospitals , Residential Intellectual and Developmental Disability, Mental Health, and Substance Abuse Facilities , Specialty (except Psychiatric and Substance Abuse) Hospitals Vocational Rehabilitation Services
View fewer
View more , Offices of Other Health Practitioners , Offices of Physicians , Other Ambulatory Health Care Services , Other Residential Care Facilities , Outpatient Care Centers , Psychiatric and Substance Abuse Hospitals , Residential Intellectual and Developmental Disability, Mental Health, and Substance Abuse Facilities , Specialty (except Psychiatric and Substance Abuse) Hospitals Vocational Rehabilitation Services
View fewer
?
?
?
Modelled
?
Actual
$445.76 million
Actual
23.46%
$1,300
DEC
?
?
NASDAQ:VCYT
Contacts
Get in Touch with 6 Principals* and 269 Contacts
-
Marc StapleyChief Executive Officer
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of December 31, 2024 (12 month period) in USD
Annual Revenue 2024
$445.76 million
USD
Actual
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Operating Cash | $75 | $44 | $8 |
| Net Investing Cash | -$56 | $15 | -$29 |
| Net Financing Cash | $5 | $3 | $3 |
| Net Change in Cash | $24 | $62 | -$18 |
| Cash at Beginning of Period | $217 | $155 | $174 |
| Cash at End of Period | $241 | $217 | $155 |
| Capital Expenditure | -$11 | -$10 | -$9 |
| Assets (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $239 | $216 | $154 |
| Accounts Receivable | $47 | $40 | $44 |
| Inventories | $22 | $16 | $14 |
| Other Current Assets | $65 | $13 | $36 |
| Asset Summary | |||
| Total Current Assets | $372 | $286 | $249 |
| Tangible Fixed Assets | $71 | $31 | $31 |
| Intangible Assets | $102 | $89 | $175 |
| Total Assets | $1,300 | $1,115 | $1,156 |
| Liabilities (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $9 | $13 | $12 |
| Short-Term Debt | $ | $ | $ |
| Other Current Liabilities | $70 | $48 | $51 |
| Liability Summary | |||
| Total Current Liabilities | $79 | $61 | $63 |
| Long-Term Debt | $ | $ | $ |
| Other Long-Term Liabilities | $1 | $1 | $3 |
| Total Liabilities | $124 | $71 | $81 |
| Stakeholder's Equity (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Equity | |||
| Common Stock | $0 | $0 | $0 |
| Retained Earnings | -$444 | -$468 | -$394 |
| Equity Summary | |||
| Total Equity | $1,176 | $1,044 | $1,075 |
| Shares Outstanding | 77,772,678 | 73,264,738 | 71,959,454 |